[144] Mineralys Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) filed a Form 144 disclosing the proposed sale of 11,366 shares of common stock. The shares—valued at an aggregate $165,878.90 based on market price at the time of filing—are expected to be sold on or about 14 July 2025 through Merrill Lynch on the NASDAQ exchange. The company reports 65,175,287 shares outstanding, so the proposed sale represents roughly 0.017 % of total shares.

The securities being sold were acquired via two cash exercises of employee stock options on 11 July 2024 (5,017 shares) and 12 July 2024 (6,349 shares). The filing also lists prior insider sales by David Rodman of an identical 11,366 shares on 14 May 2025 and again on 13 June 2025, generating $173,773.92 and $165,930.95 in gross proceeds, respectively.

No adverse information regarding Mineralys’ operations is disclosed, and the seller affirms compliance with Rule 144 and the absence of undisclosed material information. The transaction appears routine, reflecting employee option exercises followed by liquidity-driven sales, with limited dilution or strategic impact given the small percentage of shares involved.

Positive

• Very small scale: 11,366 shares equal only about 0.017 % of Mineralys’ outstanding stock, limiting dilution or market impact.

Negative

• Ongoing insider selling: This is the third consecutive month an insider has sold 11,366 shares, which may be viewed unfavorably by some investors.

Insights

Securities Analyst

TL;DR Small Rule 144 sale (0.017 % float); routine insider liquidity, limited immediate valuation impact.

This Form 144 signals a modest insider disposition—11,366 shares vs. 65.2 million outstanding—following prior monthly sales of identical size. Proceeds align with recent market pricing (~$14.60/sh). Because the shares originate from option exercises rather than open-market purchases, dilution has already occurred; the filing merely notifies a resale into the public market. Insider selling can create perception risk, yet the size and recurring pattern suggest pre-planned diversification. Absent further context around corporate developments, I view the filing as neutral for valuation and liquidity.

Corporate Governance Expert

TL;DR Continued monthly sales may raise governance optics but remain immaterial in scale.

The disclosure highlights a third consecutive month of similar-sized insider sales. While permitted under Rule 144 and presumably compliant with any 10b5-1 plan, recurring dispositions can attract investor scrutiny regarding insider sentiment. However, the absence of any undisclosed adverse information statement and the minuscule portion of outstanding shares (<0.02 %) temper governance concerns. I classify the overall impact as neutral-to-slightly negative on perception but not on fundamentals.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	11366	165878.90	65175287	07/14/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/11/2024	Cash purchase of employee stock options	Mineralys Therapeutics, Inc.			5017	07/11/2024	Cash
Common Stock	07/12/2024	Cash purchase of employee stock options	Mineralys Therapeutics, Inc.			6349	07/12/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	05/14/2025	11366	173773.92
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	06/13/2025	11366	165930.95

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Mineralys Therapeutics (MLYS) shares are being sold under this Form 144?

The notice covers the proposed sale of 11,366 common shares.

What is the approximate dollar value of the MLYS shares to be sold?

The aggregate market value is reported at $165,878.90.

When is the planned sale date for these Mineralys shares?

The approximate sale date is 14 July 2025.

What percentage of Mineralys’ total shares does this sale represent?

About 0.017 % of the 65,175,287 shares outstanding.

Were there recent insider sales of MLYS stock?

Yes, 11,366 shares were sold on 14 May 2025 and again on 13 June 2025.

How were the shares being sold acquired?

They were obtained through cash exercises of employee stock options on 11 and 12 July 2024.